首页> 外文会议>2011 International Conference on Business Management and Electronic Information >Study on supply chain of national essential medicine in China
【24h】

Study on supply chain of national essential medicine in China

机译:中国国家基本药物供应链研究

获取原文

摘要

After the implementation of national essential drugs in China, the management of the pharmaceutical supply chain faces a dilemma. The effects of national essential drug system on pharmaceutical manufacturers, distributors, hospitals and consumers were stated in this paper. In addition, the obstacles of the supply chain of national essential medicine were analyzed. Finally, the proposals for the supply chain of Chinese essential medicine were given. The essential medicines supply system should be diversified. State-owned large pharmaceutical companies and private enterprises are responsible to reduce prices in the medicine supplying market. The medium and small pharmaceutical companies should give up some common brands, but concentrate on the production of specialty products. The distribution industry should also be public-private partnerships, to comply with competition rules. The reform in public hospital should accelerate the pace from personnel system, medical service prices, the establishment of compensation mechanism of zero circulating interest. National sectors related with the pharmaceutical circulation should balance the interests of pharmaceutical supply chain, only by which could from the source to ensure the smooth advance of essential medicines policy.
机译:在中国国家精神毒品实施后,制药供应链的管理面临困境。本文规定了国家基本药物制度对制药制造商,经销商,医院和消费者的影响。此外,分析了全国本质药物供应链的障碍。最后,给出了中国本质药物供应链的建议。基本药物供应系统应多样化。国有大型制药公司和民营企业负责降低药品市场价格的价格。中小型制药公司应该放弃一些普通品牌,但专注于生产专业产品。分销行业也应该是公私伙伴关系,遵守竞争规则。公立医院改革应加快人事制度,医疗服务价格,建立零循环利益的赔偿机制。与药物流通有关的国家部门应平衡药物供应链的利益,只能通过源头来确保必要药物政策的顺利进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号